J Urol Oncol > Volume 21(3); 2023 > Article |
|
Funding/Support
We gratefully acknowledge support from the John Robinson Family Foundation, Christopher Churchill Foundation, and Cox Immunology Fund.
Author Contribution
Conceptualization: EHN, BNS, YBS, MAB, KO, VAM; Data Curation: EHN, BNS, YBS; Formal Analysis: EHN, BNS, YBS; Funding Acquisition: KO, VAM; Methodology: EHN, BNS, YBS, MAB, KO, VAM; Project Administration: MAB, KO, VAM; Visualization: EHN, BNS, YBS, MAB, KO, VAM; Writing - original draft: EHN, BNS, YBS, MAB, KO, VAM; Writing - reviewing & editing: EHN, BNS, YBS, MAB, KO, VAM.
Study | Cohort (n) | Study measurement(s) | Outcome(s) of interest | Cutoffs used | Results |
---|---|---|---|---|---|
Perioperative outcomes | |||||
Hagiwara et al. 2012 [25] | T1-3a <10 cm RCC after Laparoscopic RN (121) | BMI, VAT, SAT, TAT | Operative time | BMI ≥25.0 kg/m2 | Operative time: higher BMI exhibited a positive correlation (r=0.348, p<0.001) |
VAT area ≥100 cm2 | No BMI association in multivariable analysis | ||||
Akaihata et al. 2013 [28] | T1-2 RCC after laparoscopic RP RN (96) | BMI, anterior perirenal fat distance | Operative time | BMI ≥25.0 kg/m2 | Operative time: increasing fat distance positively correlated (r=0.252; p=0.016) |
EBL | Continuous perinephric fat distance | EBL: increasing fat distance positively correlated (r=0.336; p=0.001) | |||
Perioperative complications | No association between BMI, operative time, complications or EBL was seen | ||||
Darbas et al. 2020 [29] | Localized RCC in overweight patients (96) | BMI, SMI, VAT, SAT, IMAT | Postoperative infections | Obesity: BMI ≥30.0 kg/m2 | Infection rate: Obesity - BMI (29% vs. 8%; p=0.007) |
LOS >7 days (PN) or >10 days (RN) | Sex-specific SMI thresholds | Extended LOS: Obesity - BMI (40% vs. 22%; p=0.06) | |||
Cohort median thresholds for other BC parameters | |||||
Survival outcomes in localized RCC | |||||
Darbas et al. 2020 [29] | Localized RCC in overweight patients (96) | BMI, SMI, VAT, SAT, IMAT | 5-year DFS & OS | Obesity-BMI ≥30.0 kg/m2 | No association between BMI, DFS, or OS was seen |
Sex-specific SMI thresholds | Other BC parameters were nonsignificant | ||||
Cohort median thresholds for other BC parameters | |||||
Mano et al. 2014 [30] | AJCC stage I-III ccRCC (220) | BMI, VAT, SAT | OS | WHO BMI categorization | OS: BMI association on univariable analysis only (p=0.028) |
Cohort median thresholds for other BC parameters | No association between BC parameters and OS on multivariable analysis | ||||
Donin et al. 2016 [31] | High-risk RCC receiving adjuvant girentixumab (845) | BMI | DFS, OS | BMI categorization: <25.0; 25.0-29.9; 30.0-34.9; ≥35.0 kg/m2 | DFS: BMI 30-34.9 kg/m2 (HR, 0.77; 95% CI, 0.56-1.05); ≥35 kg/m2 (HR, 0.74; 95% CI, 0.48-1.15) |
OS: BMI 30-34.9 kg/m2 (HR, 0.50; 95% CI, 0.31-0.81); ≥35 kg/m2 (HR, 0.24; 95% CI, 0.09-0.60) | |||||
Survival outcomes in metastatic and locally advanced RCC | |||||
Steffens et al. 2011 [32] | mRCC receiving anti-VEGF therapy (116) | BMI, VAT, SAT | PFS, OS | WHO BMI categorization | PFS: low VAT (HR, 3.26; p=0.006); low SAT (HR, 2.66; p=0.010) |
Cohort median thresholds for other BC parameters | OS: low VAT (HR, 2.97; p=0.006); low SAT (HR, 3.41; p=0.001) | ||||
No association between BMI, PFS, or OS | |||||
Antoun et al. 2010 [33] | mRCC receiving sorafenib (55) | BMI, SMI | DLT | BMI ≥25.0 kg/m2 | DLT: 41% prevalence in sarcopenia + low BMI <25.0 |
Sex-specific SMI thresholds | |||||
Huillard et al. 2013 [34] | mRCC receiving sunitinib (61) | BMI, SMI | DLT | BMI ≥25.0 kg/m2 | DLT: Sarcopenia + low BMI (OR, 4.1; p=0.01) |
Sex-specific SMI thresholds | No association of BMI or sarcopenia alone with DLT | ||||
De Giorgi et al. 2019 [35] | mRCC receiving nivolumab (313) | BMI, SII, NLR, PLR | OS | BMI ≥25.0 kg/m2 | OS: low BMI (HR, 1.58; p=0.01); BMI <25.0 + SII ≥1,375 (HR, 3.37; p<0.0001) |
Optimal cutoff analysis for SII, NLR, PLR | |||||
Lalani et al. 2021 [36] | aRCC receiving ICI therapy (735) | BMI | 1-yr OS, ORR, TTF | BMI ≥25.0 kg/m2 | OS: high BMI (79% vs. 66%; HR, 0.75, p=0.03) |
ORR: high BMI (30% vs. 21%; OR, 1.51, nonsignificant) | |||||
TTF: high BMI (7.4 vs. 4.9 months; HR, 0.98, nonsignificant) | |||||
Martini et al. 2020 [37] | mRCC receiving ICI therapy (100) | BMI, MLR, distant metastases | OS, PFS | Risk score with BMI <24.0 kg/m2, MLR ≥0.93, number of distant metastases (0, 1, 2) | OS: very poor (HR, 29.5), poor (HR, 6.58), intermediate (HR, 3.75) vs. favorable risk |
PFS: very poor (HR, 2.80), poor (HR, 1.36), intermediate (HR, 1.70) vs. favorable risk | |||||
Boi et al. 2020 [38] | aRCC receiving PD-1-based therapy (73) | BMI | 2.5-yr OS, PFS | BMI ≥30.0 kg/m2 | OS: low BMI (HR, 0.48; p=0.037) |
PFS: low BMI (HR, 0.54; p=0.032) |
RCC, renal cell carcinoma; RN, radical nephrectomy; BMI, body mass index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; RP, retroperitoneal; EBL, estimated blood loss, mL; SMI, skeletal muscle index; IMAT, intermuscular adipose tissue; PN, partial nephrectomy; LOS, length of stay, days; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; BC, body composition; AJCC, American Joint Cancer Committee; cc, clear cell; WHO, World Health Organization; mRCC, metastatic RCC; VEGF, vascular endothelial growth factor; DLT, dose-limiting toxicity; SII, systemic immune inflammation index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ICI, immune checkpoint inhibitor; MLR, monocyte-to-lymphocyte ratio; PFS, progression-free survival; ORR, objective-response rate; TTF, time-to-treatment failure; aRCC, advanced RCC; PD-1, programmed cell death protein 1.
Study | Cohort (n) | Study measurement(s) | Outcome(s) of interest | Cutoffs Used | Results |
---|---|---|---|---|---|
Perioperative outcomes | |||||
Watanabe et al. 2021 [42] | Advanced RCC after nephrectomy and IVC thrombectomy (83) | SMI | Operative time | Sex-specific SMI thresholds | Operative time: sarcopenia (366 min vs. 372 min; p=0.974) |
EBL | EBL: sarcopenia (1,750 mL vs. 1740 mL; p=0.903) | ||||
Postoperative complications | Complications: sarcopenia (any grade, 35.2% vs. 27.6%; p=0.482) | ||||
LOS | LOS: sarcopenia (11 days vs. 10 days; p=0.148) | ||||
Schmeusser et al. 2023 [43] | Non-mRCC after nephrectomy and IVC thrombectomy (115) | SMI | 90-day high-grade complications | Sex-specific SMI thresholds | No association with preoperative sarcopenia (HR, 2.04; 95% CI, 0.66-6.42) |
Peyton et al. 2016 [44] | AJCC stage III-IV RCC after RN (128) | PMI | EBL | Sex-specific cohort quartiles (sarcopenia = bottom quartile) | EBL: sarcopenia (613 mL vs. 809 mL; p=0.49) |
LOS | LOS: sarcopenia (6.0 days vs. 4.7 days; p=0.15) | ||||
High-grade complications | Clavien grade ≥III complication: sarcopenia (18% vs. 5%; OR, 4.2; p=0.03) | ||||
Survival outcomes in localized RCC | |||||
Psutka et al. 2016 [46] | Non-mRCC after RN (387) | SMI | 5-yr CSS, OS | Sex-specific SMI thresholds | CSS: sarcopenia (79% vs. 85%; HR, 1.70; p=0.047) |
OS: sarcopenia (65% vs. 74%; HR, 1.48; p=0.039) | |||||
Noguchi et al. 2020 [48] | Localized ccRCC in males (316) | PMI | 5-yr RFS | Cohort median threshold for PMI | RFS: Low PMI (HR, 2.31; p=0.022) |
Mao et al. 2021 [49] | Localized RCC after PN or RN (443) | SMI, PMI | 5-yr CSS, OS | Sex-specific SMI, PMI thresholds | OS: sarcopenia (SMI-HR, 2.9; p<0.001) & (PMI-HR, 2.8; p<0.001) |
CSS: sarcopenia (SMI-HR, 2.6; p=0.009) & (PMI-HR, 2.2; p=0.031) | |||||
Lee et al. 2022 [47] | pT1-2 RCC after RN (632) | SMI | 10-yr CSS, OS | Sex-specific SMI thresholds | OS: sarcopenia (HR, 2.58; p=0.045) |
CSS: sarcopenia (HR, 3.07; p=0.006) | |||||
Midenberg et al. 2023 [50] | Localized RCC after PN or RN (473) | SMI, Albumin | 10-yr RFS, CSS, OS | Sex-specific SMI threshold | OS: Sarcopenia + hypoalbuminemia (HR, 2.62; p<0.001) |
Albumin <3.5 g/dL | RFS: Sarcopenia + hypoalbuminemia (HR, 2.42; p=0.003) | ||||
CSS: Sarcopenia + hypoalbuminemia (HR, 2.98; p=0.007) | |||||
No association between sarcopenia alone and OS, RFS, or CSS | |||||
Darbas et al. 2020 [29] | Localized RCC in overweight patients (96) | BMI, SMI, VAT, SAT, IMAT | 5-yr DFS & OS | Obesity-BMI ≥30.0 kg/m2 | DFS: no associations between BC parameters |
Sex-specific SMI thresholds | OS: no associations between BC parameters | ||||
Cohort median thresholds for other BC parameters | |||||
Makino et al. 2023 [51] | Non-mRCC after PN or RN (299) | PMI | 10-yr OS, CSS, MFS | Optimal cutoff analysis for PMI | OS: Sarcopenia (HR, 2.58; p=0.030) |
MFS: Sarcopenia (HR, 1.18; p=0.628) | |||||
CSS: No significant association with sarcopenia (p=0.207) | |||||
Survival outcomes in metastatic and locally advanced RCC | |||||
Fukushima et al. 2016 [54] | mRCC at initial diagnosis (92) | SMI | 3-yr OS | Sex-specific SMI thresholds | OS: Sarcopenia (31% vs. 73%; HR, 2.58; p=0.015) |
Sharma et al. 2015 [55] | mRCC after CN (93) | SMI | OS | Sex-specific SMI thresholds | OS: Sarcopenia (7 mo vs. 23 mo; HR, 2.13; p=0.016) |
Khan et al. 2022 [56] | mRCC after CN (158) | SMI, VAT, SAT, IMAT | OS | Sex-specific SMI thresholds | OS: Sarcopenia negatively associated (15.0 mo vs. 29.4 mo; p=0.04) |
Cohort median thresholds for other BC measures | No significant associations with adiposity parameters | ||||
Lee et al. 2021 [57] | mRCC receiving sunitinib (78) | SMI | PFS, OS | Sex-specific SMI thresholds | Mean dose reduction: Sarcopenia (20.3% vs. 6.3%; p=0.004) |
Dose reduction | PFS: Sarcopenia (HR, 2.62; p=0.001) | ||||
OS: Sarcopenia (HR, 1.79; p=0.038) | |||||
Antoun et al. 2010 [33] | mRCC receiving sorafenib (55) | BMI, SMI | DLT | BMI ≥25.0 kg/m2 | DLT: 41% prevalence in sarcopenia + low BMI |
Sex-specific SMI thresholds | |||||
Huillard et al. 2013 [34] | mRCC receiving sunitinib (61) | BMI, SMI | DLT | BMI ≥25.0 kg/m2 | DLT: Sarcopenia + low BMI (OR, 4.1; p=0.01) |
Sex-specific SMI thresholds | |||||
Aslan et al. 2022 [58] | mRCC receiving ICI therapy (52) | SMI, Albumin, NLR | OS, PFS | Cohort median threshold for cachexia index [(SMI x albumin)/NLR] | OS: Low index (7 mo vs. 48 mo; HR, 4.5; p=0.001) |
PFS: Low index (4 mo vs. 17 mo; HR, 2.6; p=0.007) | |||||
No association of sarcopenia alone with OS or PFS | |||||
Ged et al. 2022 [59] | mccRCC receving ICI therapy (205) | BMI, SMI, VAT, SAT | 2-yr OS, PFS | BMI ≥25.0 kg/m2 | OS: Sarcopenia (HR, 1.65; p=0.009); High BMI (HR, 0.66; p=0.036) |
Sex-specific SMI thresholds | No association with Sarcopenia & high BMI after IMDC score adjustment | ||||
Cohort median thresholds for other BC parameters | No association with adiposity parameters and OS | ||||
Fukushima et al. 2017 [60] | mRCC after CN (37) | SMI | 3-yr OS | Continuous & % change categorization for SMI | 3-yr OS rates: 19% (>5% SMI loss), 76% (stable SMI), 100% (>5% SMI gain) |
Gu et al. 2017 [61] | mRCC receiving targeted therapy (101) | SMI | PFS, OS | % change in SMI | OS: positive SMI% change (HR, 0.92; p<0.001) PFS: ≥5% SMI loss (HR, 1.744; p=0.024) |
OS: ≥5% SMI loss (HR, 2.367; p=0.008) | |||||
Ozaki et al. 2023 [62] | mRCC receiving targeted therapy (57) | PMI | PFS, OS | % change in PMI | PFS: ≥10% PMI loss (HR, 3.35; p=0.043) |
OS: ≥10% PMI loss (HR, 4.95; p=0.011) | |||||
Kazemi-Bajestani et al. 2018 [63] | mRCC receiving sorafenib or sunitinib (47) | SMI, TAT | Cardiotoxicity (LVEF fall >10% to absolute <55%) | % change in SMI | High TAT associated with toxicity (87.5% vs. 41.0%; p=0.02) |
Sex-specific TAT median threshold | % SMI change greater in patients with toxicity (-7% vs. 0%; p=0.04) |
RCC, renal cell carcinoma; IVC, inferior vena cava; SMI, skeletal muscle index; EBL, estimated blood loss; HR, hazard ratio; CI, confidence interval; LOS, length of stay; mRCC, metastatic RCC; AJCC, American Joint Cancer Committee; RN, radical nephrectomy; PMI, psoas muscle index; CSS, cancer-specific survival; OS, overall survival; ccRCC, clear cell RCC; PN, partial nephrectomy; RFS, recurrence-free survival; BMI, body mass index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; IMAT, intermuscular adipose tissue; DFS, disease-free survival; BC, body composition; MFS, metastasis-free survival; CN, cytoreductive nephrectomy; DLT, dose-limiting toxicity; ICI, immune checkpoint inhibitor; NLR, neutrophil-to-lymphocyte ratio; IMDC, International Metastatic RCC Database Consortium; LVEF, left ventricular ejection fraction; TAT, total adipose tissue.
Study | Cohort (n) | Study measurement(s) | Outcome(s) of interest | Cutoffs used | Results |
---|---|---|---|---|---|
Perioperative outcomes | |||||
Hagiwara et al. 2012 [25] | T1-3a <10 cm RCC after laparoscopic RN (121) | BMI, VAT, SAT, TAT | Operative time | BMI ≥25.0 kg/m2 | Higher BMI (r=0.316; p<0.001) & VAT (r=0.348; p<0.001) showed a correlation |
VAT area ≥100 cm2 | Obesity: VAT alone associated with operative time (OR, 3.70; p=0.009) | ||||
Zhai et al. 2018 [70] | AJCC stage I-III ccRCC after RN (76) | BMI, VAT | Operative time | BMI <28.0 kg/m2 (Chinese obesity threshold) | Operative time: High VAT (172 vs. 141 min; p=0.012); High BMI (197 min vs. 153 min; p=0.013) |
EBL LOS | EBL: High VAT (132 mL vs. 84 mL; p=0.018); High BMI (215 mL vs. 93 mL; p=0.013) | ||||
Complications | VAT area >100 cm2 | Complications: High VAT alone (26.9% vs. 4.2%; p=0.045) | |||
Total expenses | LOS: High VAT alone (8.7 days vs. 7.5 days; p=0.013) | ||||
Total expenses: High VAT ($7.6k vs. $2.7k; p=0.040); High BMI ($8.4k vs. $6.9k; p=0.029) | |||||
Yuge et al. 2015 [71] | Laparoscopic RN (167) | VAT | Operative time | VAT ≥100 cm2 | High VAT with nonexpert surgeon (<50 cases/year) associated with prolonged time (HR, 5.15; p=0.004) |
Mean operating time threshold | |||||
Darbas et al. 2020 [29] | Localized RCC after PN or RN in overweight patients (96) | BMI, SMI, VAT, SAT, IMAT | Postoperative infections | WHO BMI categorization | No significant associations of BC parameters with perioperative outcomes measured, except BMI ≥30.0 with increased risk of infections and LOS |
LOS >7 days (PN) or >10 days (RN) | Sex-specific SMI thresholds | ||||
Cohort median thresholds for adiposity | |||||
Demirel & Dilek 2023 [72] | Localized RCC after PN or RN (210) | SMI, VAT, SAT, IMAT | High-grade complications | Continuous | No associations between BC parameters in patients with versus without HG complications |
Akaihata et al. 2013 [28] | T1-2 RCC after laparoscopic RP RN (96) | BMI, anterior perirenal fat distance | Operative time | BMI ≥25.0 kg/m2 | Operative time: anterior perirenal fat (r=0.252; p=0.016) |
EBL | Continuous fat distances | EBL: anterior perirenal fat (r=0.336; p=0.001) | |||
Complications | No significant association with BMI ≥25.0 | ||||
Gorin et al. 2013 [73] | Localized RCC after MIPN (257) | BMI, VAT, SAT | Operative time | Continuous BC measurements | All-grade complications: VAT only (OR, 1.05; p=0.005) |
Complications | High-grade complications: VAT only (OR, 1.05; p=0.040) | ||||
LOS | No significant associations with operative time or LOS | ||||
Raman et al. 2016 [74] | Localized RCC after RPN (240) | Perinephric fat, perinephric to subcutaneous fat ratio | Ischemic time | Continuous BC measurements | All-grade complications: perinephric to subcutaneous fat ratio (OR, 1.82; p=0.020) |
EBL | |||||
Complications | No other significant associations with high-grade complications, operative time, ischemic time, or EBL | ||||
LOS | |||||
Ioffe et al. 2013 [75] | Localized RCC after MIPN (118) | VAT, SAT, perinephric fat | Ischemic time | Cohort-specific tertiles for adiposity parameters | No significant associations of adiposity parameters with perioperative outcomes measured |
EBL | |||||
Complications | |||||
Davidiuk et al. 2014 [76] | Localized RCC after RPN (100) | MAP score | Adherent perinephric fat | Posterior perinephric fat | Presence of adherent fat: MAP score 0 (6%), 1 (16%), 2 (31%), 3-4 (73%), 5 (100%) |
Lateral perinephric fat | |||||
Perinephric fat stranding | |||||
Survival outcomes in localized RCC | |||||
Naya et al. 2010 [77] | Localized RCC after PN or RN (117) | VAT | Pathologic features, CSS | Cohort median threshold for VAT | Low VAT associated with advanced disease (AJCC II-IV, p=0.022), microvascular invasion (p=0.026), decreased CSS (p=0.026) |
Maurits et al. 2022 [67] | AJCC Stage I-III RCC (719) | SMI, SMD, VAT, SAT | OS, RFS | Sex-specific median thresholds for BC parameters | OS: low VAT (Men: HR, 1.38; 95% CI, 1.05-1.83) & (Women: HR, 1.67; 95% CI, 1.01-2.78) |
RFS: low VAT-Men only (HR, 1.46; 95% CI, 1.03-2.05) | |||||
Park et al. 2014 [78] | Localized RCC after PN or RN (706) | VAT%, VAT, SAT, TAT | RFS | Cohort VAT% Quartiles | RFS: VAT% (lowest quartile: HR, 3.2; p=0.036) & (highest quartile: HR, 4.8; p=0.010) |
Kaneko et al. 2015 [79] | Localized RCC after PN or RN (285) | VAT | 5-yr RFS | VAT area ≥120 cm2 | RFS rates: all histologies, low VAT (76.9% vs. 91.3%; p=0.037) |
Low VAT only predictor of RFS in ccRCC (HR, 1.974; p=0.042) | |||||
Preza-Fernandes et al. 2022 [80] | Localized RCC after PN or RN (137) | SMI, VAT, SAT, perinephric fat | PFS, OS | Cohort tertiles for BC parameters | PFS: high perinephric fat area (HR, 0.3; p=0.019) |
OS: high perinephric fat area (HR, 0.3; p=0.009) | |||||
Maurits et al. 2022 [82] | AJCC Stage I-IV RCC (1039) | BMI, SMI, VAT, SAT, TAT, VAT% | Pathologic features, TNM stage | 10-unit BC parameter increases | Stage IV in males: VAT (OR, 0.93; p<0.001), TAT (OR, 0.95; p<0.001), VAT% (OR, 0.97; p<0.001) |
Stage IV in females: VAT only (OR, 0.95; p<0.05) | |||||
No significant associations of body composition with tumor grade | |||||
Tan et al. 2022 [83] | Localized vs. mRCC (188) | BMI, SMI, SAT, VAT | BC differences according to RCC stage | Continuous comparison | VAT: localized vs. mRCC (1986.7 vs. 1523.2 cm3; p=0.020) |
No associations with other BC parameters and higher-stage RCC | |||||
Thiel et al. 2016 [81] | Localized RCC (456) | MAP score | PFS | Dichotomized MAP score: low (1-3) vs. high (4-5) | PFS: High MAP (HR, 2.20; p=0.032) |
Survival outcomes in metastatic and locally aRCC | |||||
Steffens et al. 2011 [32] | mRCC receiving anti-VEGF therapy (116) | BMI, VAT, SAT | PFS, OS | Cohort median thresholds for BC parameters | PFS: Low VAT (HR, 3.26; p=0.006); Low SAT (HR, 2.66; p=0.010) |
OS: Low VAT (HR, 2.97; p=0.006); Low SAT (HR, 3.41; p=0.001) | |||||
Ladoire et al. 2011 [84] | mRCC receiving anti- VEGF therapy (113) | BMI, VAT, SAT | PFS, OS | Cohort median thresholds for BC parameters | PFS: High VAT (HR, 3.07; p=0.011); SAT nonsignificant |
OS: High VAT (HR, 6.26; p=0.001); SAT nonsignificant | |||||
Gu et al. 2015 [85] | aRCC receiving targeted therapy (124) | VAT, SAT | OS | Continuous & sex-specific optimal cutoff analysis | OS: association with higher VAT (HR, 0.981; p=0.002) & higher SAT (HR, 0.987; p=0.048) |
OS: low VAT only (HR, 2.087; p=0.007) | |||||
Ning et al. 2022 [86] | mRCC receiving anti-VEGF therapy (358) | BMI, VAT, SAT, perinephric fat | PFS, OS | BMI <24.0 kg/m2 | PFS: High perinephric fat (HR, 0.78; 95% CI, 0.61-0.98) |
Cohort median thresholds for BC parameters | OS: High perinephric fat (HR, 0.57; 95% CI, 0.35-0.93) | ||||
No other significant parameter association on multivariable analysis | |||||
Park et al. 2020 [88] | mRCC receiving sunitinib (311) | BMI, VAT, SAT | DLT, PFS, CSS | Continuous & Cohort median thresholds for BC parameters | DLT: increasing VAT (OR, 1.013; p=0.029) |
PFS: Low VAT (13.0 vs. 26.0 months; p=0.006) | |||||
CSS: No significant associations with body composition | |||||
Kazemi-Bajestani et al. 2018 [63] | mRCC receiving sorafenib or sunitinib (47) | SMI, TAT | Cardiotoxicity (LVEF fall >10% to absolute <55%) | % change in SMI; sex-specific median threshold for TAT | High TAT associated with toxicity (87.5% vs. 41.0%; p=0.02) |
% SMI change greater in patients with toxicity (-7% vs. 0%; p=0.04) | |||||
Martini et al. 2021 [89] | mRCC receiving ICI therapy (79) | SMI, SAT, IMAT, VAT, TAT | PFS, OS, ORR | Cohort optimal cutoff analysis | OS: poor risk (HR, 6.37; p<0.001); low TAT (HR, 2.72; p=0.002) |
Risk score including IMAT, SAT | PFS: poor risk (HR, 4.19; p<0.001); low TAT (HR, 1.91; p=0.025) | ||||
ORR: poor risk (OR, 0.23; p=0.044); low TAT (OR, 0.25; p=0.008) | |||||
Wang et al. 2023 [90] | mRCC receiving ICI therapy (224) | BMI, SMI, VAT, SAT, SAT% | PFS, OS | Continuous BC parameters | PFS: SAT% (HR, 0.02; 95% CI, 0.00-0.04) |
OS: SAT% (HR, 0.08; 95% CI, 0.01-0.72) | |||||
Schmeusser et al. 2023 [87] | T3-4 locally aRCC (141) | MAP Score | PFS, OS | Dichotomized MAP score: low (1-3) vs. high (4-5) | No significant associations between MAP and PFS or OS |
RCC, renal cell carcinoma; RN, radical nephrectomy; BMI, body mass index; VAT, visceral adipose tissue; OR, odds ratio; HR, hazard ratio; CI, confidence interval; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; AJCC, American Joint Cancer Committee; ccRCC, clear cell RCC; EBL, estimated blood loss; LOS, length of stay; PN, partial nephrectomy; IMAT, intermuscular adipose tissue; WHO, World Health Organization; SMI, skeletal muscle index; BC, body composition; HG, high-grade; RP, retroperitoneal; MI, minimally invasive; RPN, robotic PN; MAP, Mayo Adhesive Probability; CSS, cancer-specific survival; SMD, skeletal muscle density; RFS, recurrence-free survival; OS, overall survival; PFS, progression-free survival; mRCC, metastatic RCC; VEGF, vascular endothelial growth factor; DLT, dose-limiting toxicity; LVEF, left ventricular ejection fraction; ORR, objective-response rate; ICI, immune checkpoint inhibitor; aRCC, advanced RCC.
Edouard H. Nicaise
https://orcid.org/0009-0002-4885-3144
Benjamin N. Schmeusser
https://orcid.org/0000-0002-0762-3388
Yash B. Shah
https://orcid.org/0000-0003-1551-7611
Mehmet A. Bilen
https://orcid.org/0000-0003-4003-1103
Kenneth Ogan
https://orcid.org/0000-0001-7715-3724
Viraj A. Master
https://orcid.org/0000-0002-7251-142X